Clinical Scorecard: Assessment of Liver Stiffness as a Predictor for Sinusoidal Obstructive Syndrome Following Hematopoietic Stem Cell Transplantation
At a Glance
Category
Detail
Condition
Sinusoidal Obstructive Syndrome (SOS) after hematopoietic stem cell transplantation (HSCT)
Key Mechanisms
Injury to sinusoidal endothelial cells causing sinusoidal obstruction, hepatic congestion, and post-sinusoidal portal hypertension
Target Population
Adult patients undergoing allogeneic HSCT, especially those at high risk for SOS
Care Setting
Hematology and transplant centers performing allogeneic HSCT
Key Highlights
SOS incidence in adults post-HSCT is approximately 10%, with severe cases having up to 80% mortality.
Risk factors include pre-existing liver disease, prior chemotherapy, high-intensity conditioning regimens, and older age.
Liver stiffness measurement (LSM) by transient elastography can increase after SOS onset but baseline LSM does not predict SOS.
Guideline-Based Recommendations
Diagnosis
Use EBMT clinical criteria including bilirubin >2 mg/dl for SOS diagnosis.
Consider differential diagnoses such as viral reactivation, sepsis, drug-induced liver injury, GVHD, and vascular thrombosis.
Use imaging adjunctively to detect liver congestion and portal hypertension but recognize its limited specificity.
Management
Modify conditioning regimens in high-risk patients with elevated LSM (>7 kPa) to lower toxicity options to reduce SOS risk.
Monitoring & Follow-up
Perform LSM before and after HSCT to assess liver stiffness changes.
Monitor bilirubin levels and clinical signs of SOS within 21 days post-transplant.
Risks
High-dose Busulfan, total body irradiation, dual alkylating agents, and methotrexate-based GVHD prophylaxis increase SOS risk.
Pre-existing liver abnormalities and multiple prior therapies elevate SOS risk.
Patient & Prescribing Data
Adults undergoing allo-HSCT with or without elevated bilirubin and liver stiffness
Patients with LSM >7 kPa before HSCT had conditioning regimens adjusted to lower toxicity to mitigate SOS risk; baseline LSM alone did not predict SOS development.
Clinical Best Practices
Assess liver stiffness using transient elastography pre- and post-HSCT for early detection of SOS.
Apply EBMT criteria rigorously for SOS diagnosis, considering clinical and laboratory parameters.
Adjust conditioning regimens based on LSM to reduce SOS incidence in high-risk patients.
Use imaging as an adjunct to clinical assessment but not as a sole diagnostic tool for SOS.
Monitor patients closely for bilirubin elevation and clinical signs within the first 21 days post-transplant.
